| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Department of Ophthalmology and Visual Science and the 3Section of Cellular Physiological Chemistry, Tokyo Medical and Dental University, Tokyo, Japan; and the 2Discovery Research Laboratories, Shionogi and Co., Ltd., Osaka, Japan.
PURPOSE. To study the putative role of endogenous matrix metalloproteinases (MMPs) in retinal neovascularization, an established mouse model was used to compare the retinal neovascularization observed in wild-type mice with that in mice without the MMP-2 or -9 genes.
METHODS. C57Bl/6 (MMP-2+/+ and -9+/+), MMP-2–deficient (MMP-2-/-), and MMP-9–deficient (MMP-9-/-) mice were used. After oxygen-induced retinopathy was induced in the mice, their eyes were rapidly removed and frozen in optimal cutting temperature embedding compound. Sections were histochemically stained with specific markers for vascular cells and angiogenesis-related factors. The area of new retinal vessels was measured using image-analysis software and compared between groups.
RESULTS. Retinal neovascularization was not significantly different between wild-type and MMP-9-/- mice. The MMP-2-/- mice had significantly less extraretinal neovascularization than did wild-type mice. The mean number of extraretinal neovascular buds per cross section was significantly lower in MMP-2-/- mice than in wild-type mice (P < 0.05). The expression of other angiogenesis-related factors, vascular endothelial growth factor and pigment epithelium-derived factor, was not different between wild-type and MMP-2-/- mice.
CONCLUSIONS. MMP-2 may be essential in the regulation of retinal neovascularization. Pharmacologic intervention using MMP inhibitors may be a future therapeutic approach for angiogenic retinal diseases.
This article has been cited by other articles:
|
|
 |
|
  M. Gerg, C. Kopitz, S. Schaten, A. Tschukes, C. Kahlert, M. Stangl, C. W. Hann von Weyhern, B. L.D.M. Brucher, D. R. Edwards, K. Brand, et al. Distinct Functionality of Tumor Cell-Derived Gelatinases during Formation of Liver Metastases Mol. Cancer Res., March 1, 2008; 6(3): 341 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Dean, G. S. Butler, Y. Hamma-Kourbali, J. Delbe, D. R. Brigstock, J. Courty, and C. M. Overall Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis Mol. Cell. Biol., December 15, 2007; 27(24): 8454 - 8465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Zayed, W. Yuan, T. M. Leisner, D. Chalothorn, A. W. McFadden, M. D. Schaller, M. E. Hartnett, J. E. Faber, and L. V. Parise CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis Circ. Res., November 26, 2007; 101(11): 1185 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Cockle, N. Gopichandran, J. J. Walker, M. I. Levene, and N. M. Orsi Matrix Metalloproteinases and Their Tissue Inhibitors in Preterm Perinatal Complications Reproductive Sciences, October 1, 2007; 14(7): 629 - 645. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Barnett, G. W. McCollum, J. A. Fowler, J. J.-W. Duan, J. D. Kay, R.-Q. Liu, D. P. Bingaman, and J. S. Penn Pharmacologic and Genetic Manipulation of MMP-2 and -9 Affects Retinal Neovascularization in Rodent Models of OIR Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 907 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Cummins, N. von Offenberg Sweeney, M. T. Killeen, Y. A. Birney, E. M. Redmond, and P. A. Cahill Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H28 - H42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ispanovic and T. L. Haas JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells Am J Physiol Cell Physiol, October 1, 2006; 291(4): C579 - C588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xu, Y. Yu, and E. J. Duh Vascular Endothelial Growth Factor Upregulates Expression of ADAMTS1 in Endothelial Cells through Protein Kinase C Signaling. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 4059 - 4066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Rutkowski, K. C. Boardman, and M. A. Swartz Characterization of lymphangiogenesis in a model of adult skin regeneration Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1402 - H1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhang, R. G. Fahmy, N. diGirolamo, and L. M. Khachigian JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation J. Cell Sci., August 1, 2006; 119(15): 3219 - 3226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lee, S. Dahi, R. Mahimkar, N. L. Tulloch, M. A. Alfonso-Jaume, D. H. Lovett, and R. Sarkar Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia PNAS, November 8, 2005; 102(45): 16345 - 16350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Notari, A. Miller, A. Martinez, J. Amaral, M. Ju, G. Robinson, L. E. H. Smith, and S. P. Becerra Pigment Epithelium-Derived Factor Is a Substrate for Matrix Metalloproteinase Type 2 and Type 9: Implications for Downregulation in Hypoxia Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2736 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Boyd, J. Doyle, E. Gee, S. Pallan, and T. L. Haas MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2 Am J Physiol Cell Physiol, March 1, 2005; 288(3): C659 - C668. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
